MedTech Dive March 28, 2024
Medtech dealmaking has not yet taken off this year, but there have been a number of smaller tuck-in acquisitions and private equity agreements.
Wall Street analysts tipped 2024 as the year that medtech dealmaking would return after a two-year slowdown when companies were forced to navigate a tough economic environment, complicated by the COVID-19 pandemic still pressuring businesses.
There have been few big-name, billion-dollar deals so far this year, though a steady amount of M&A news has come out of the sector.
In early January, Boston Scientific announced it would buy Axonics for $3.7 billion. The acquisition, which Axonics’ shareholders approved last week, has been the largest announced yet in 2024. Boston Scientific may still have a few hurdles to...
Today's Sponsors
Today's Sponsor